The company is working on a potential rapid diagnostic test for the highly infectious Bundibugyo strain
York life sciences business Aptamer has announced it has started developing a potential diagnostic test for Ebola. The company, which develops synthetic binders for the life sciences industry, is working on a potential rapid diagnostic test for the highly infectious Bundibugyo strain of the Ebola virus.
An outbreak of the strain started in the Democratic Republic of Congo and Uganda in May – the largest recorded outbreak of the rare strain – and the World Health Organization has declared both an epidemic and a public health emergency.
Fatality rates for the Bundibugyo strain of Ebola range from approximately 30% to 50%, depending on factors including virus strain, the quality of patient care quality, and how quickly it is picked up and treated. Early detection is critical to patient outcomes and outbreak containment.
Unlike the more common Zaire strain of Ebola, for which vaccines and treatments exist, current diagnostic tests struggle to rapidly and reliably identify Bundibugyo.
In a note to shareholders, Aptamer said its Optimer technology has previously demonstrated rapid responses in diagnostic applications to support the response to infectious disease outbreaks. During the COVID-19 pandemic, Aptamer developed SARS-CoV-2 binders that were successfully translated into lateral flow tests.
The firm says the global Ebola testing market was valued at $1.2bn in 2025 and is projected to grow from $1.3bn in 2026 to $2.3bn by 2033.
Within this, the market in North America dominated with a revenue share of 40.9% in 2025.
The new programme will aim to develop Optimer binders suitable for integration into rapid, field-compatible diagnostic tests for Bundibugyo Ebola and work has started immediately.
Dr Arron Tolley, chief executive officer of Aptamer Group, said: “Those following the Ebola outbreak in Sub-Saharan Africa will note the growing severity of the situation on both a human and economic level.
“The head of the Africa Centres for Disease Control and Prevention, Director-General Jean Kaseya, has warned that containing this outbreak could cost billions of dollars. A critical limiting factor in response is rapid, accurate diagnosis. Existing tests lack the sensitivity needed for timely detection in field settings.
“During COVID, our platform demonstrated its ability to deliver diagnostic tools at pace to respond to infectious disease outbreaks. We are now applying that capability to develop Optimers for specific proteins of the Bundibugyo strain. With development under way in our labs, I look forward to updating shareholders as the programme progresses.”







You must be logged in to post a comment Login